PRDM14 and breast carcinoma: Our findings add a new layer of evidence to the epigenetic landscape of breast cancer, providing convincing clues that MAST1, PRDM14, and ZNF177 are differentially methylated in breast cancer, as well as that they may serve as potential drivers and biomarkers for breast cancer.